Endothelin-1 and asymmetric dimethylarginine in children with left-to-right shunt after intracardiac repair (Clinical Research in Cardiology (February 2008) 97, (383-388) DOI: 10.1007/s00392-008-0645-x);Endothelin-1 and asymmetric dimethylarginine in children with left-to-right shunt after intracardiac repair

Clinical Research in Cardiology

Volumn 97, Issue 6, 2008, Pages 383-388

  Loukanov, Tsvetomir ^a   Arnold, Raoul ^b   Gross, Jasmin ^a   Sebening, Christian ^a   Klimpel, Homa ^a   Eichhorn, Joachim ^a   Hoss, Katharina ^a   Ulmer, Herbert E ^a   Kark, Matthias ^a   Gorenflo, Matthias ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Endothelin 1; Extracorporeal circulation; Lung; Pulmonary hypertension

Indexed keywords

ENDOTHELIN 1; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE SYNTHASE;

ADOLESCENT; ADULT; ARTICLE; CARDIOPULMONARY BYPASS; CHILD; CLINICAL ARTICLE; FEMALE; HEART ATRIUM SEPTUM DEFECT; HEART LEFT RIGHT SHUNT; HUMAN; INFANT; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MALE; POSTOPERATIVE CARE; PREOPERATIVE EVALUATION; PULMONARY HYPERTENSION; TRICUSPID VALVE DISEASE;

EID: 46149105219     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-008-0687-0     Document Type: Erratum

References (20)

1. Argaman Z, Young VR, Noviski N, Castillo-Rosas L, Lu X-M, Zurakowski D, Cooper M, Davison C, Tharakan JF, Ajami A, Castillo L (2003) Arginine and nitric oxide metabolism in critically ill septic pediatric patients. Crit Care Med 31:591-597
2. Bando K, Vijayaraghavan P, Turrentine MW, Sharp TG, Ensing GJ, Sekine Y, Szekely L, Morelock RJ, Brown JW (1997) Dynamic changes of endothelin-1, nitric oxide, and cyclic GMP in patients with congenital heart disease. Circulation 96(suppl II): II346-II351
3. Barr FE, Beverly H, VanHook K, Cermak E, Christian K, Drinkwater D, Dyer D, Raggio NT, Moore JH, Christmann B, Summar M (2003) Effect of cardiopulmonary bypass on urea cycle intermediates and nitric oxide levels after congenital heart surgery. J Pediatr 142:26-30
4. Böger RH (2005) Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials. Vasc Med 10(Suppl 1):S19-S25
5. Capper SJ, Ella SJ, Kalinka S (1991) Development and application of three radioimmunoassays of endothelin of varying specificities. J Cardiovasc Pharmacol 17(Suppl 7):S425-S426
6. Duke T, South M, Stewart A (1997) Altered activation of the l-arginine nitric oxide pathway during and after cardiopulmonary bypass. Perfusion 12:405-410
7. Ewert R, Opitz CF, Wensel R, Winkler J, Halank M, Felix SB (2007) Continuous intravenous iloprost to revert treatment failure of first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Clin Res Cardiol 96:211-217
8. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, Duguid WP, Stewart DJ (1993) Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 328:1732-1739
9. Gorenflo M, Zheng Ch, Werle E, Fiehn W, Ulmer HE (2001) Plasma levels of asymmetrical dimethyl-l-arginine in patients with congenital heart disease and pulmonary hypertension. J Cardiovasc Pharmacol 37:489-492
10. Gorenflo M, Ullmann MV, Eitel K, Gross J, Fiehn W, Hagl S, Dreyhaupt J (2005) Plasma l-arginine and metabolites of nitric oxide synthase in patients with left-to-right shunt after intracardiac repair. Chest 127:1184-1189
11. G-dimethyl-l- arginine in plasma by liquid chromatography as AccQ-Fluor™ fluorescent derivates. J Chromatogr 805:325-329
12. Karu I, Zilmer K, Starkopf J, Zilmer M (2006) Changes of plasma asymmetric dimethylarginine levels after coronary artery bypass grafting. Scand Cardiovasc J 40:363-367
13. Kähler J, Mendel S, Weckmüller J, Orzechowski HD, Mittmann C, Köster R, Paul M, Meinertz T, Münzel T (2000) Oxidative stress increases synthesis of big endothelin-1 by activation of the endothelin-1 promoter. J Mol Cell Cardiol 32:1429-1437
14. Kielstein JT, Bode-Böger SM, Hesse G, Martens-Lobenhoffer J, Takacs A, Fliser D, Hoeper MM (2005) Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol 25:1414-1418
15. Mizuno Y, Isotani E, Ohno K, Nagai A, Imamura M, Azuma H (2007) Involvement of accumulated NOS inhibitors and endothelin-1, enhanced arginase, and impaired DDAH activities in pulmonary dysfunction following subarachnoid hemorrhage in the rabbit. Vascul Pharmacol 2007 November 17 [epub ahead of print]
16. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Koerner SK (1987) Primary pulmonary hypertension. A national prospective study. Ann Intern Med 107:216-223
17. Rosenkranz S (2007) Pulmonary hypertension: current diagnosis and treatment. Clin Res Cardiol 96:527-541
18. Usui M, Matsuoka H, Miyazaki H, Ueda S, Okuda S, Imaizumi T (1998) Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sci 62:2425-2430
19. Valkonen VP, Paiva H, Salonen JT, Lakka TA, Lehtimaki T, Laakso J, Laaksonen R (2001) Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 358:212-228
20. Wilkinson JL (2001) Haemodynamic calculations in the catheter laboratory. Heart 85:113-120